An add-on Study to the FIGARO-DKD Study Called FIGARO-BM to Learn About the Link Between Biomarkers (Substances in the Blood Used as Indicators of Biological Processes, Disease Processes or Responses to Medication) and Finerenone in FIGARO-DKD Participants

A phase 2 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 951 participants.

Also called NCT05013008

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; no masking; primary purpose other
Phase
Phase 2
Enrolled
  • 951 participants (enrolled count) (from the registry)
Sponsor
  • Bayer Registry lists this organization as the lead sponsor
Registry
  • NCT NCT05013008
  • EudraCT 2021-003053-37
Started
(actual) (from the registry)
Primary completion
(actual) (from the registry)
Completion
(actual) (from the registry)
Results first posted
(from the registry)
Countries
United States, Australia, Austria, Belgium, Bulgaria, Canada, Czechia, Denmark, Finland, Hong Kong SAR China, Israel, Italy, Japan, Netherlands, Portugal, Russia, Singapore, South Korea, Spain, Sweden, Taiwan (from the registry)
Registry status
  • Completed (from the registry)

Technical summary

Registry record NCT05013008. Randomized; no masking; primary purpose other. Start 2021-08-18 (actual); primary completion 2021-12-31 (actual). Results posted on 2023-03-31.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
An add-on Study to the FIGARO-DKD Study Called FIGARO-BM to Learn About the Link Between Biomarkers (Substances in the Blood Used as Indicators of Biological Processes, Disease Processes or Responses to Medication) and Finerenone in FIGARO-DKD Participants
Acronym
FIGARO-BM
Condition
Type 2 Diabetes Mellitus
Intervention (Drug)
Finerenone (Kerendia, BAY94-8862)
Intervention (Drug)
Placebo
Lead sponsor
Bayer (class: industry)

Record details

Record id
cardio:ct-nct05013008
Content hash
474a8c3ffe032ff53bfe7f834fb41360ab42ced74e730c2080164cf1b53799fd